Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Grifols S.A. ADR (GRFS)

Grifols S.A. ADR (GRFS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,913,016
  • Shares Outstanding, K 687,560
  • Annual Sales, $ 7,135 M
  • Annual Income, $ 64,200 K
  • EBIT $ 1,216 M
  • EBITDA $ 1,695 M
  • 60-Month Beta 0.50
  • Price/Sales 0.79
  • Price/Cash Flow 10.72
  • Price/Book 0.67

Options Overview Details

View History
  • Implied Volatility 71.11% ( unch)
  • Historical Volatility 47.54%
  • IV Percentile 31%
  • IV Rank 37.66%
  • IV High 166.84% on 03/07/24
  • IV Low 13.27% on 06/07/24
  • Put/Call Vol Ratio 5.50
  • Today's Volume 65
  • Volume Avg (30-Day) 325
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 26,943
  • Open Int (30-Day) 30,304

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.24
  • Number of Estimates 1
  • High Estimate 0.24
  • Low Estimate 0.24
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.11 +3.82%
on 10/29/24
9.96 -15.46%
on 11/08/24
-0.15 (-1.75%)
since 10/21/24
3-Month
7.13 +18.09%
on 09/25/24
9.96 -15.46%
on 11/08/24
+0.75 (+9.78%)
since 08/21/24
52-Week
5.30 +58.86%
on 03/06/24
12.15 -30.70%
on 12/29/23
-1.13 (-11.83%)
since 11/21/23

Most Recent Stories

More News
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 0.8739 (+0.44%)
CSTL : 28.45 (-1.45%)
GRFS : 8.42 (-2.09%)
SPRO : 1.1989 (-0.09%)
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain

/PRNewswire/ -- DelveInsight's 'Dry Eye Disease Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline dry eye disease therapies in...

GRFS : 8.42 (-2.09%)
Why Shares of Grifols Were Up Tuesday

The company gave first-quarter numbers.

GRFS : 8.42 (-2.09%)
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...

GRF : 10.50 (+1.35%)
GRFS : 8.42 (-2.09%)
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease

/PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research,...

GRFS : 8.42 (-2.09%)
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is...

GRF : 10.50 (+1.35%)
GRFS : 8.42 (-2.09%)
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...

GRF : 10.50 (+1.35%)
GRFS : 8.42 (-2.09%)
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...

GRF : 10.50 (+1.35%)
GRFS : 8.42 (-2.09%)
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

These three healthcare stocks should hold their value for years.

BAYRY : 5.1400 (-4.10%)
TAK : 13.34 (+0.38%)
GRFS : 8.42 (-2.09%)
Illumina Ventures Announces Promotion and Additions to its Investment Team

Illumina Ventures , today announced the promotion of Malek Faham, MD, PhD, to Chief Scientist having previously served as both a Venture Partner and Entrepreneur in Residence (EIR). In addition, Charles...

ADPT : 4.56 (+3.17%)
AFFX : 14.01 (+0.14%)
CSTL : 28.45 (-1.45%)
GRFS : 8.42 (-2.09%)
NTRA : 169.92 (+1.22%)
ILMN : 131.94 (+0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

3rd Resistance Point 8.91
2nd Resistance Point 8.76
1st Resistance Point 8.68
Last Price 8.42
1st Support Level 8.45
2nd Support Level 8.29
3rd Support Level 8.21

See More

52-Week High 12.15
Fibonacci 61.8% 9.53
Fibonacci 50% 8.73
Last Price 8.42
Fibonacci 38.2% 7.92
52-Week Low 5.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar